Healthcare Industry News: M. D. Anderson Cancer Center
News Release - February 26, 2008
NCCN Updates Ovarian Cancer GuidelinesFORT WASHINGTON, Pa.--(HSMN NewsFeed)--The National Comprehensive Cancer Network (NCCN) is pleased to announce several new updates to the NCCN Clinical Practice Guidelines in OncologyTM Ovarian Cancer. These changes highlight leading developments in the treatment of ovarian cancer and represent the recognized standard for clinical care in oncology in both the community and the academic practice settings.
Patients with ovarian cancer were once thought to exhibit no symptoms during the early stage of the disease. But recent studies have shown that a specific set of symptoms are more common in women with ovarian cancer than women in the general population. This early-symptom list, collected and codified by the Gynecologic Cancer Foundation, has been incorporated into the NCCN Ovarian Cancer Guidelines. Symptoms suggestive of ovarian cancer include: bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly and urinary symptoms such as urgency or frequency. Awareness of the possible significance of these symptoms may enable earlier identification of women with ovarian cancer, even those with early-stage cancer.
The other major update to these guidelines is that the treatment regimens for ovarian cancer, germ cell tumors and ovarian stromal tumors have been expanded to include new chemotherapeutic agents, to indicate which agents are preferred and to clarify which agents should be used for specific tumors.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.
For more information, visit www.nccn.org.
The NCCN Member Institutions are: City of Hope, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, Columbus, OH; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.
Source: National Comprehensive Cancer Network
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.